Navigation Links
Ipilimumab in advanced melanoma: added benefit for non-pretreated patients not proven
Date:6/12/2014

In early 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ipilimumab in non-pretreated patients with advanced melanoma. The drug manufacturer claimed a noticeable increase in survival time and thus an added benefit versus dacarbazine, the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). However, the indirect comparison conducted by the company was too uncertain, and the postulated effect was biased in favour of ipilimumab. Hence an added benefit was not proven.

In two addenda, the Institute now also examined updated and corrected analyses by the company as well as a possible added benefit versus a second comparator therapy. The result remained unchanged, however: An added benefit of ipilimumab is not proven for non-pretreated patients versus any of the two comparator therapies.

Advantage in pretreated patients

Ipilimumab is a monoclonal antibody used in melanoma if the disease is so advanced that the melanoma can no longer be surgically removed or has formed metastases. In 2012, the manufacturer presented informative data for pretreated patients from a randomized controlled trial. These data indicated a major advantage of ipilimumab in survival time in comparison with "best supportive care". This advantage was associated with major risk of harm, however.

Effects in non-pretreated patients not interpretable

In October 2013, European approval was expanded to patients who have not been treated for their advanced melanoma. In a new dossier, the manufacturer subsequently also claimed an added benefit for this group versus the appropriate comparator therapy dacarbazine specified by the G-BA. IQWiG did not concur with this claim because the treatment effects presented by the manufacturer were not interpretable: The quality of the relevant indirect unadjusted comparison was too low, the results were biased in favour of ipilimumab, and not all relevant confounders were considered in the analysis.

Subsequent assessment in two addenda

In addition, the manufacturer had presented data on the comparison of ipilimumab with vemurafenib in its dossier. IQWiG did not examine these data in its dossier assessment because the G-BA had not specified vemurafenib as an appropriate comparator therapy at first. In March 2014, shortly before completion of the IQWiG dossier assessment, the G-BA commissioned the Institute to also assess the potential added benefit versus vemurafenib. Moreover, the manufacturer submitted corrected and updated data analyses in the commenting procedure on the dossier assessment in April 2014. Following the G-BA's commission, IQWiG now assessed these data in a second addendum.

Indirect comparison not interpretable

As so far there are no studies that directly compare ipilimumab with vemurafenib, the manufacturer used an indirect comparison, in which dacarbazine was used as a so-called common comparator. In this indirect comparison, on the one hand it used data from the BRIM-3 study, a randomized phase 3 study comparing vemurafenib with dacarbazine.

For the second side of the indirect comparison, the manufacturer did not use a direct comparison between ipilimumab and dacarbazine. Instead, it used the unadjusted indirect comparison again, which it had already used for examining the added benefit in comparison with dacarbazine. Hence the indirect comparison between ipilimumab and vemurafenib is also subject to great uncertainties. No conclusions on added benefit can be derived from this.

General weakness of analysis not resolved

In the second addendum, the Institute examined the corrected analyses subsequently submitted by the manufacturer. This correction reduced the exclusion of patients, but, in the outcome "overall survival", the exclusion was still 20 percentage points higher on the ipilimumab side of the indirect comparison than on the dacarbazine side. Originally, the difference was almost 40 percentage points.

What is more important, however, is the fact that the documents subsequently submitted did not address the uncertainty resulting from the methods of the unadjusted indirect comparison. Overall, an added benefit of ipilimumab in non-pretreated patients with advanced melanoma versus dacarbazine or vemurafenib is still not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the G-BA conducted commenting procedures, in which the manufacturer submitted additional information. The G-BA subsequently commissioned IQWiG to assess the data subsequently submitted.

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The Institute sent the two addenda on ipilimumab to the commissioning agency on 26 March and on 16 May 2014.

The G-BA then decides on the extent of the added benefit in each case, thus completing the early benefit assessment.


'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Marker may predict response to ipilimumab in advanced melanoma
2. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
3. Considerable added benefit of ipilimumab in advanced melanoma
4. Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm
5. Early palliative support services help those caring for patients with advanced cancer
6. UIC conducts phase I drug study for advanced pancreatic cancer
7. Long-term results encouraging for combination immunotherapy for advanced melanoma
8. Immune therapy for advanced bladder cancer yields promising results
9. Better sleep predicts longer survival time for women with advanced breast cancer
10. Drinking poses greater risk for advanced liver disease in HIV/hep C patients
11. Palliation is rarely a topic in studies on advanced cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National ... organizations, advocates, and individuals join together to increase recognition about the risks of ... lives. , “Today we mark a nationwide movement to raise awareness about a ...
(Date:2/22/2017)... TX (PRWEB) , ... February 22, 2017 , ... ... the launch of ProGen™ PRP, the latest innovation in the delivery of Platelet ... wound care, aesthetics, cardiovascular and pain management, to accelerate tissue synthesis and provide ...
(Date:2/22/2017)... CT (PRWEB) , ... February 22, 2017 , ... The ... and the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A ... webinar is part of the Interactive Webinar Series. , If you want to find ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... veterans who suffer from combat-related PTSD. , Established in 1977, our organization was ... the challenges of military returning to civilian life were evident and served as ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb 22, 2017 Research and Markets ... Analysis & Trends - Industry Forecast to 2025" report to their ... The Global Clot ... 5.2% over the next decade to reach approximately $2.1 billion by 2025. ... forecasts for all the given segments on global as well as regional ...
(Date:2/22/2017)... Research and Markets has announced the addition of the ... Trend Indicator):Analysis By Region, By Country (2016-21)" report to their ... Global ... CAGR of 5.33% during 2016-2021 The strong growth is ... demand of digital thermometer. Apart from that, the downfall in the ...
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
Breaking Medicine Technology: